Unlike the case with acute myeloid leukemia, there is limited information on the prognostic impact of isocitrate dehydrogenase (IDH) mutations in myelodysplastic syndromes (MDS). In the current study of 277 patients with MDS, IDH mutations were detected in 34 (12%) cases: 26 IDH2 (all R140Q) and 8 IDH1 (6 R132S and 2 R132C). Mutational frequency was 4% (2 of 56) in refractory anemia with ring sideroblasts, 12% (16 of 130) in refractory cytopenia with multilineage dysplasia, 14% (2 of 14) in MDS-unclassifiable, 14% (6 of 42) in refractory anemia with excess blasts (RAEB)-1 and 23% (8 of 35) in RAEB-2. Normal karyotype was noted in all but one IDH1-mutated cases and 13 IDH2-mutated cases. Multivariable analysis identified presence of mutant IDH1 (P ¼ 0.0004; hazard ration 4.0, 95% confidence interval 1.9 -8.8), revised International Prognostic Scoring System risk category (Po0.0001), and red cell transfusion need (P ¼ 0.002) as independent predictors of inferior survival. In a similar multivariable analysis, mutant IDH1 was the only variable associated with shortened leukemia-free survival (P ¼ 0.001; hazard ration 7.0, 95% confidence interval 2.3 -20.8). The presence of IDH2R140Q did not affect the overall (P ¼ 0.54) or leukemia-free (P ¼ 0.81) survival. The current study suggests a powerful adverse prognostic effect for mutant IDH1 in MDS.
Introduction
Isocitrate dehydrogenase (IDH) mutations occur in the majority of patients with low-grade gliomas and are prognostically favorable in that context. 1 A smaller proportion of patients with acute myeloid leukemia (AML) and other myeloid malignancies also harbor both IDH1 and IDH2 mutations; reported mutational frequencies are approximately 10% for AML, 2 -5 5% for myelodysplastic syndromes (MDS), 6, 7 4% for myeloproliferative neoplasms (MPN), 5, 8 9% for MDS/MPN, 7 15% for post-MDS AML, 6 22% for post-MPN AML, 8 10% for post-MDS/MPN AML, 7 22% for del(5q)-associated high-risk MDS or AML 9 and 4% for blast-phase chronic myelogenous leukemia (B4%). 10 In AML, IDH mutations cluster with normal or intermediaterisk karyotype, sole trisomy 8 and NPM1 mutations. 3,11 -14 Mutant IDH1 in AML has been associated with poor prognosis in cytogenetically normal AML with NPM1 þ /FLT3 -molecular profile 4, 15, 16 and better prognosis in FLT3 þ AML. 12 In some 4 but not other 17 studies, mutant IDH2 was associated with unfavorable prognosis in cytogenetically normal AML, 4 whereas a more recent study suggested that mutant IDH2R140 was prognostically more favorable than mutant IDH2R172. 18 There is currently limited information on the prognostic impact of IDH mutations in MDS and other chronic myeloid malignancies. 6, 8 We recently reported on IDH1 and IDH2 mutational frequencies among 1473 patients with BCR-ABL1-negative MPN, 8 1 -4% in chronic-phase MPN and approximately 25% in blast-phase polycythemia vera or primary myelofibrosis. Subsequently, we examined the prognostic impact of IDH mutations in chronic-phase primary myelofibrosis and showed inferior overall and leukemia-free survival in the presence of IDH mutations. 19 In the current study, we examined the phenotypic and prognostic effects of IDH1 and IDH2 mutations among 277 patients with MDS, in the context of the recently revised International Prognostic Scoring System (IPSS-R) and other previously acknowledged risk factors. 20 
Materials and methods
The current study was approved by the Mayo Clinic institutional review board. Study eligibility criteria included availability of bone marrow histology and cytogenetic information at time of referral to the Mayo Clinic. The diagnoses of MDS and leukemic transformation (LT) were according to the World Health Organization criteria. 21 Karyotype risk designation and risk stratification were according to the revised IPSS-R. 20 All study patients were fully characterized for karyotype IDH1, IDH2, JAK2 and MPL mutational status.
DNA from bone marrow or peripheral blood was extracted using conventional methods. MPL and JAK2 mutation analyses were performed according to previously published methods. 22 -25 IDH1 and IDH2 mutations were analyzed by direct sequencing and/or high-resolution melting assay. Direct sequencing for IDH1 exon 4 mutations was done using the following primer sequences: sense, 5 Overall survival was calculated from the date of first referral to date of death (uncensored) or last contact (censored). Leukemia-free survival was calculated from the date of first referral to date of LT (uncensored) or death/last contact (censored). Overall and leukemia-free survival curves were prepared by the Kaplan -Meier method and compared by the log-rank test. Cox proportional hazard regression model was used for multivariable analysis. P-values less than 0.05 were considered significant. The Stat View (SAS Institute, Cary, NC, USA) statistical package was used for all calculations.
Results
Two hundred and seventy-seven consecutive patients with MDS seen at the Mayo Clinic from 2000 to 2005 were included in the study. The median age of the cohort was 71 years (range, 21 -91 years), with 72% of the patients being males. Table 1 describes the presenting clinical and laboratory features and subsequent events in the 277 study patients with MDS, stratified by the presence or absence of IDH mutations. Fifty-two (19%) patients were red cell transfusion-dependent at diagnosis, and none of the patients had clinical or laboratory evidence for transfusional hemosiderosis.
IDH mutations were detected in 34 (12%) cases: 26 IDH2 and 8 IDH1. Mutational frequency was 4% (2 of 56) in refractory anemia with ring sideroblasts (RARS), 12% (16 of 130) in refractory cytopenia with multilineage dysplasia, 14% (2 of 14) in MDS-unclassifiable, 14% (6 of 42) in refractory anemia with excess blasts (RAEB)-1 and 23% (8 of 35) in RAEB-2. Table 2 describes the IDH mutation type, WHO histological category, karyotype and the IPSS-R prognostic scores of the 34 patients with IDH mutations. Among patients with IDH1 mutations, two (25%) were IDH1 R132C mutant, whereas the remainder was Table 1 Presenting clinical and laboratory features and subsequent events in 277 patients with myelodysplastic syndromes, stratified by the presence or absence of IDH mutations
Variable
All patients (n ¼ 277)
Patients without IDH mutations (n ¼ 243) IDH1 R132S mutant. Seven patients (88%) with IDH1 mutations, including all six IDH1 R132S mutants had a normal karyotype. Patients with IDH1 mutations presented with a lower white blood cell count (median 2.2, range 1 -4.7) and were all transfusion-dependent at diagnosis. Among patients with IDH2 mutations, 25 (96%) were IDH2 R140Q mutant, whereas one patient carried both the IDH2 R140Q and R140W mutations. This patient was a 77-year-old male with RAEB-1, who had a normal bone marrow karyotype (IPSS-R-good) and died secondary to pneumonia 4 months after diagnosis. Five patients (2%) carried the JAK2 V617F mutation, two with RARS and three with refractory cytopenia with multilineage dysplasia. The patients with RARS had a low JAK2 allele burden (o10%), normal karyotype and low-to-normal platelet counts. They did not meet the WHO histological criteria for RARSthrombocytosis. There was one patient (o0.5%) who had the MPL W515L mutation; a 61-year-old male with refractory cytopenia with multilineage dysplasia, mild thrombocytopenia and a normal karyotype.
To date, 225 (81%) deaths and 49 (18%) LTs have occurred. Among the 49 LT, 4 had IDH1 mutations and 5 had IDH2 mutations, constituting 50% and 19% of the total number of patients with IDH1 and IDH2 mutations, respectively. Notably, there were no cases of LT amongst the patients with JAK2 or MPL mutations. Forty-six (94%) patients with LT were dead at last follow-up, including six (85%) of seven that had undergone allogenic peripheral blood stem cell transplantation. All nine (100%) patients with IDH mutations and LT had died.
Multivariable analysis that included IDH1 and IDH2 mutations as separate categories, risk stratification by both WHOdefined histology and the IPSS-R prognostic scores, bone marrow karyotype and red-cell transfusion dependence identified presence of mutant IDH1 (P ¼ 0.001), IPSS-R (Po0.0001) and transfusion need (P ¼ 0.002) as independent predictors of inferior survival (Figures 1,2 and Table 3 ). In a similar analysis, mutant IDH1 was the only detrimental factor for leukemia-free survival (P ¼ 0.001) (Figure 3 and Table 4 ). The presence of mutant IDH2 did not affect the overall (P ¼ 0.54) or leukemiafree (P ¼ 0.81) survival (Tables 3 and 4) .
Discussion
IDH1 and IDH2 catalyze oxidative decarboxylation of isocitrate to a-ketoglutarate. Recently described IDH mutations encode proteins that have deficient activity in this regard, but express neomorphic catalytic activity in converting a-ketoglutarate to 2-hydroxyglutarate. 26 -29 Currently known IDH mutations in- volve exon 4 and affect three specific arginine residues: R132 (IDH1), R172 (IDH2) and R140 (IDH2). 8 The oncogenic mechanism of mutant IDH is incompletely understood and both decreased supply of a-ketoglutarate and abnormal accumulation of 2-hydroxyglutarate have been implicated in this regard. 26, 30 The prognostic impact of IDH mutations in AML has been studied extensively. 3,11 -14 In contrast, very few studies have looked into this matter in chronic myeloid malignancies. Both IDH1 and IDH2 mutations occur in MDS, although some studies 6 have reported a preponderance of IDH1 mutations, whereas others have shown the opposite. 7 In the current MDS study, the overwhelming majority of IDH mutations were IDH2R140Q. In MDS and other myeloid neoplasms associated with sole del(5q), the presence of mutant IDH has been associated with inferior overall and leukemia-free survivals. 6, 9, 31 Of note, the MDS study showing a detrimental prognostic effect of mutant IDH involved only IDH1 mutations. 6 The current study signifies the adverse prognostic effect of mutant IDH1 on both overall and leukemia-free survival in MDS. This is similar to what has been observed in AML and consistent with a recent report in MDS that underlined the detrimental effect of IDH1 mutations in MDS. 6 Interestingly, the authors of the particular study did not find IDH2 mutations in their study cohort. A similar clinical observation was made in a recent report that showed an inferior leukemia free survival in IDH-mutated myeloid malignancies with isolated del(5q). 31 Whether or not therapeutic targeting of mutant IDH or interfering with the production/function of its 'oncogenic' metabolite (i.e., 2-hydroxyglutarate) would favorably affect leukemic progression in primary myelofibrosis remains to be seen.
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